Loading...
Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium
Fonseca, A. Lobo, J. Hazard, F.K. Gell, J. Weiss, R.S. Klosterkemper, L. Volchenboum, S.L. Nicholson, J.C. Frazier, A.L.
Fonseca, A.
Lobo, J.
Hazard, F.K.
Gell, J.
Weiss, R.S.
Klosterkemper, L.
Volchenboum, S.L.
Nicholson, J.C.
Frazier, A.L.
Publication Date
2022-11
End of Embargo
Supervisor
Rights
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons licence, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this licence, visit http://
creativecommons.org/licenses/by/4.0/.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2022-09-23
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Germ cell tumours (GCTs) are a heterogeneous group of rare neoplasms that present in different anatomical sites and across a wide spectrum of patient ages from birth through to adulthood. Once these strata are applied, cohort numbers become modest, hindering inferences regarding management and therapeutic advances. Moreover, patients with GCTs are treated by different medical professionals including paediatric oncologists, neuro-oncologists, medical oncologists, neurosurgeons, gynaecological oncologists, surgeons, and urologists. Silos of care have thus formed, further hampering knowledge dissemination between specialists. Dedicated biobank specimen collection is therefore critical to foster continuous growth in our understanding of similarities and differences by age, gender, and site, particularly for rare cancers such as GCTs. Here, the Malignant Germ Cell International Consortium provides a framework to create a sustainable, global research infrastructure that facilitates acquisition of tissue and liquid biopsies together with matched clinical data sets that reflect the diversity of GCTs. Such an effort would create an invaluable repository of clinical and biological data which can underpin international collaborations that span professional boundaries, translate into clinical practice, and ultimately impact patient outcomes.
Version
Published version
Citation
Fonseca A, Lobo J, Hazard FK et al (2022) Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium. British Journal of Cancer. 127: 1577-1583.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article